Found 1 Presentation For Request "1784p"
1784P - Targeting FGFR signaling with FGFR inhibitor-based regimens: UCSD molecular tumor board experience
- Yuji Uehara (Bunkyo-ku, Japan)
Abstract
Background
Genomic alterations in the FGF/FGFR pathway are emerging as promising therapeutic targets. However, not all patients respond to therapy and resistance occurs. We investigated the molecular characteristics of patients (pts) treated with FGFR inhibitor-based therapies, including combination approaches.
Methods
We reviewed pts presented at the Molecular Tumor Board who received FGFR inhibitor to target FGFR pathway alterations. Pt demographics, molecular characteristics, therapy, response, progression-free survival (PFS), and overall survival (OS) were evaluated.
Results
Seventeen pts (pan-cancer diagnosis) with FGFR pathway alterations received FGFR inhibitors (median age: 61, male N=7 [41.2%]). The most common diagnosis was gastroesophageal cancer (29.4%), followed by biliary cancer (17.6%). FGF/FGFR amplification (amp) occurred in 13 pts, single nucleotide variant (SNV) in 3 pts, and fusions in 2 pts (N=1 patient had both amp and SNV). The most frequently co-altered pathways/genes were:
Conclusions
Most tumors with FGFR pathway abnormalities had co-genomic alterations. Targeting FGFR signaling achieved a clinical benefit rate of 35% (median duration= 14 months) in the pan-cancer setting.
Legal entity responsible for the study
University of California San Diego.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.